☰

Empresas y finanzas

Rodman & Renshaw Global Healthcare Conference 2007 Presenter Profiles


    Rodman & Renshaw Global Healthcare Conference 2007 takes place May
    14 - 15, 2007 at the Le Meridien Beach Plaza Hotel in Monte Carlo,
    Monaco. For in-depth information about the event, visit
    http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf20.

    Listed below are Rodman & Renshaw Global Healthcare Conference
    2007 presenter profiles. Business Wire is the official news wire for
    the Rodman & Renshaw Global Healthcare Conference. Breaking news
    releases are available at Tradeshownews.com, Business Wire's trade
    show, conference, and event news resource.

    -0-
    *T
    Company: Accentia Biopharmaceuticals, Inc.
    Ticker Symbol & Exchange: NASDAQ: ABPI
    Investor Relations Contact: Adam S. Holdsworth, 212-825-3210
    Web: www.accentia.net
    Date of Presentation: 5/14/2007
    Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company
    focused on the development of late-stage "disruptive" clinical
    products, especially for already-approved drugs in new formulations
    and/or new indications that are patent-protected and which represent
    new therapeutics with greater clinical and economic value. Accentia
    has a pipeline of products in late-stage clinical development. The
    company's lead respiratory product candidate is SinuNase(TM), which
    is under clinical development to treat chronic sinusitis
    (rhinosinusitis). SinuNase is a novel application and formulation of
    a known anti-fungal exclusively licensed from the Mayo Foundation for
    Medical Education and Research. The product has been Fast Tracked by
    the FDA and the Company has commenced a Phase 3 clinical trial. The
    Company's other lead product is BiovaxID(TM), a patient-specific
    anti-cancer vaccine for the treatment of follicular non-Hodgkin's
    lymphoma. BiovaxID, which is being developed by Accentia's
    subsidiary, Biovest International, Inc. (OTCBB: BVTI), is currently
    in a Fast-Tracked Phase 3 clinical trial. Through Biovest, the
    Company also manufactures AutovaxID(TM), an FDA approved commercial-
    stage automated cell-manufacturing device that enables the cost-
    effective and scalable production of proteins and other cell-based
    products. Accentia is also proposing to enter a Phase 3 clinical
    trial for Multiple Sclerosis using Revimmune(TM), which uses an
    approved drug in an exclusively licensed method of therapy to
    "reboot" a patient's immune system. Revimmune was developed at the
    Johns Hopkins School of Medicine for the elimination of autoimmunity,
    and Accentia has acquired the exclusive worldwide rights for all
    autoimmune diseases. For further information, please visit
    www.accentia.net.

    Company: Accera, Inc.
    Investor Relations Contact: Meghan Feeks, Richard Lewis
    Communications, Inc., 212.827.0020
    Web: www.accerapharma.com
    Date of Presentation: Tuesday, May 15, 11:30 a.m.
    Accera, Inc. is a private biopharmaceutical company focused on the
    discovery and development of novel therapeutics for neurodegenerative
    diseases. Based on a deep understanding of the neuronal metabolism
    defects commonly observed in CNS diseases, Accera's proprietary
    neuron energetics technology platform is being used to develop drugs
    in multiple indications including Alzheimer's disease, age-associated
    memory impairment, Parkinson's disease, and canine cognitive
    dysfunction. Through its own small molecule discovery program, in-
    licensing, and the acquisition of clinical compounds with
    demonstrated safety and efficacy, Accera continues to build a strong
    and diversified product pipeline.

    Company: Altegen, Inc
    Investor Relations Contact: Martin Atterby, 49 172 4583865 / 49 172
    4583866
    Web: www.altegen.com
    Date of Presentation: 15.05.2007
    Altegen has developed "samfor" blood tests for the pre-symptomatic /
    symptomatic diagnosis of major human diseases. "Samforad" detects
    expression of an AD-specific Beta-amyloid precursor protein "ALZAS"
    (protein and RNA) and an anti-ALZAS auto-antibody. Anti-ALZAS/ALZAS
    blood levels enable determination of staging of AD and probably of
    the efficacy of therapeutic treatments. Launch for Samforad is
    September 2007. Anti-ALZAS vaccine clinical trial phases I/II starts
    February 2008. "Samformad" screens human blood for BSE by detecting
    "Prionins." Ready-for-use-PrPSc is produced in minutes by converting
    in vitro (in test tubes) all species of native or recombinant PrP
    using prionins. European patents have been granted.

    Company: Alteon Inc
    Ticker Symbol & Exchange: ALT
    Investor Relations Contact: Noah Berkowitz, 201 818 5877
    Web: www.alteon.com
    Date of Presentation: 14-May-07
    Alteon is a product-based biopharmaceutical company engaged in the
    development of drugs to treat and prevent cardiovascular diseases,
    particularly among patients with diabetes.

    ALT-2074, is a glutathione peroxidase mimetic shown to protect
    myocardium in preclinical models of heart attack. The drug is in
    clinical development for reducing the morbidity and mortality
    following MI, in patients with diabetes and a variant of an high risk
    biomarker called haptoglobin. Alagebrium chloride is an Advanced
    Glycation End-product Crosslink Breaker being developed for diastolic
    heart failure and nephropathy. These diseases represent a rapidly
    growing market of unmet medical need, particularly common among
    diabetic patients.

    Company: Aus Bio Limited
    Investor Relations Contact: Dr Peter Jenkins - Executive Director,
    (61) 411 88 46 42
    Web: www.ausbio.com.au
    Date of Presentation: 14th May, 2007 0820 hrs. - Zephyr Salon
    AusBio is a medicinal biochemistry company. By linking the discipline
    of molecular medicine, new drug candidates have been created, for
    disease states, which are large and require new therapeutics. The
    Company's principal scientists have a proven track record of
    international commercial success following innovative R & D.
    Principal projects include diabetes mellitus, chronic wound healing,
    chronic hepatitis B & C, immune modulators and acute/chronic
    respiratory conditions. Lead candidate selection and Proof of Concept
    has occurred with the diabetes and wound healing projects, the latter
    now entering a Phase II study. All I.P. created in house and owned
    outright.

    Company: Avalon Pharmaceuticals, Inc.
    Ticker Symbol & Exchange: NASDAQ: AVRX
    Investor Relations Contact: David M. Muth, 301-556-9900 (U.S.)
    Web: Avalonrx.com
    Date of Presentation: Monday, May 14, at 3:15 p.m. CEST (Central
    European Summer Time), 9:15 a.m. EDT
    (Eastern Daylight Time).
    Avalon Pharmaceuticals is a biopharmaceutical company focused on the
    discovery and development of potential first-in-class cancer
    therapeutics. Avalon has a lead product in Phase I clinical
    development (AVN944), preclinical programs to develop inhibitors for
    the Beta-catenin and Aurora pathways, discovery programs for Survivin
    and Myc pathway inhibitors, and value generating partnerships with
    Merck, MedImmune, Medarex, and Novartis. By utilizing AvalonRx(R) our
    platform technology, based upon the proprietary use of large-scale
    gene expressions, we are uniquely positioned to develop therapeutics
    focused on pathways that have historically been characterized as
    "undruggable." Avalon was established in 1999 and is headquartered in
    Germantown, Maryland.

    Company: Axcan Pharma Inc.
    Ticker Symbol & Exchange: NASDAQ Global Market: AXCA / Toronto Stock
    Exchange: AXP
    Investor Relations Contact: Isabelle Adjahi, 450-467-2600 ext. 2000
    (Canada)
    Web: www.axcan.com
    Date of Presentation: 5/15/2007
    Axcan is a leading multinational specialty pharmaceutical company
    focused on gastroenterology. The company develops and markets a broad
    line of prescription products to treat a range of gastrointestinal
    diseases and disorders such as inflammatory bowel disease, irritable
    bowel syndrome, cholestatic liver diseases and complications related
    to pancreatic insufficiency. Axcan's products are marketed by its own
    specialized sales forces in North America and Europe.

    Company: BioLineRx Ltd.
    Ticker Symbol & Exchange: Tel Aviv: BLRX
    Investor Relations Contact: Yuri Shoshan, VP Finance and Corporate
    Development, 972-2-548-9100
    Email: yuri@biolinerx.com
    Web: www.biolinerx.com
    Date of Presentation: May 14, 2007, 4:40 PM ET
    BioLineRx is Israel's leading drug development company. Partnering
    with researchers, universities and biotech companies, BioLineRx
    advances projects from early stage discovery and lead generation to
    advanced clinical trials, regulatory approval and marketing. The
    Company was founded in 2003 by leaders in the Israeli life science
    arena including Teva Pharmaceuticals Ltd., venture capital firms
    Giza, Pitango and Hadasit, the technology transfer company of
    Hadassah hospital.

    The Company's leading programs are for the treatment of schizophrenia
    and damaged heart tissue post-myocardial infarction. Additional
    products under development include compounds for the treatment of
    cancer and CNS, cardiovascular, metabolic, infectious and autoimmune
    diseases.

    Company: Bionovo, Inc
    Ticker Symbol & Exchange: BNVI
    Investor Relations Contact: Jim Stapleton, jim@bionovo.com;
    510.601.2000
    Web: www.bionovo.com
    Date of Presentation: Mon. May 14th 8:40am
    Bionovo (BNVI) is a publicly traded pharmaceutical company focused on
    discovering and developing drugs for women's health and cancer.
    Bionovo is a leader in systems-biology integration with candidates
    designed to address specific targets associated with the regulation
    of pathological conditions. The company is working simultaneously on
    two distinct discovery approaches, one focusing on pro-apoptotic
    agents for cancer and a second, in the area of selective estrogen
    receptor modulators (SERMS) to treat severe menopausal symptoms. Both
    approaches are highly selective to yield products that will
    effectively and safely address these areas of high unmet need. The
    company's clinical development strategy leverages relationships with
    key faculty at leading research institutions to conduct trials with
    recognized opinion leaders.

    Company: BioSante Pharmaceuticals, Inc.
    Ticker Symbol & Exchange: Amex: BPA
    Investor Relations Contact: Phillip Donenberg, 847-478-0500 ext 101
    Web: www.biosantepharma.com
    Date of Presentation: 14-May-07
    BioSante is developing a pipeline of hormone therapy products to treat
    both men and women. BioSante's lead products include Elestrin(TM)
    (estradiol gel), developed through FDA approval by BioSante,
    indicated for the treatment of moderate-to-severe vasomotor symptoms
    associated with menopause, and LibiGel(R) (transdermal testosterone
    gel) in Phase III development for the treatment of female sexual
    dysfunction (FSD). The company also is developing its calcium
    phosphate nanotechnology (CaP) for novel vaccines, including
    hepatitis B, avian flu and biodefense vaccines for toxins such as
    anthrax, as well as a system for delivering drugs via alternative
    routes of administration.

    Company: DOV Pharmaceutical, Inc.
    Ticker Symbol & Exchange: DOVP.PK (Pink Sheets)
    Investor Relations Contact: Matthew Moore, 732-907-3667
    Web: www.dovpharm.com
    Date of Presentation: Tuesday, May 15, 2007
    DOV is a biopharmaceutical company focused on the discovery,
    acquisition and development of novel drug candidates for CNS
    disorders. We have active drug development programs that are at the
    preclinical, Phase I and Phase II clinical stages, including DOV
    21,947 (entering Phase II for depression), DOV 102,677 (Phase I for
    alcohol abuse) and an active preclinical discovery program in
    reuptake inhibitors and GABA modulators. We have entered into a
    sublicensing agreement with Neurocrine Biosciences, for indiplon for
    the treatment of insomnia and with XTL Development, for bicifadine
    for the treatment of pain. We are seeking a partner for DOV diltiazem
    for the treatment of angina and hypertension.

    Company: DURECT Corporation
    Ticker Symbol & Exchange: DRRX; Nasdaq
    Investor Relations Contact: Matthew J. Hogan, 408-777-4936
    Web: www.durect.com
    Date of Presentation: 14-May-07
    DURECT Corporation is an emerging specialty pharmaceutical company
    developing pharmaceutical systems based on its proprietary drug
    delivery platform technologies. The Company currently has a number of
    late-stage pharmaceutical products in development addressing large
    markets in pain management, with a number of research programs
    underway targeting chronic disease and other therapeutic areas. For
    more information, please visit www.durect.com.

    Company: EntreMed, Inc.
    Ticker Symbol & Exchange: ENMD
    Investor Relations Contact: Ginny Dunn, 240-864-2643
    Web: www.entremed.com
    Date of Presentation: Monday, May 14, 2007
    EntreMed, Inc. is a clinical-stage pharmaceutical company focused on
    developing multi-mechanism oncology drugs that target disease cells
    directly and the blood vessels that nourish them.

    EntreMed's goal is to develop and commercialize therapeutics based on
    the Company's scientific expertise in angiogenesis, cell cycle
    regulation and inflammation -- processes vital to the progression of
    cancer and other diseases. The Company's three clinical product
    candidates are based on these mechanisms. The Company's expertise has
    also led to the identification of new molecules, including new
    chemical entities derived from 2ME2, as well as new chemical entities
    associated with multi-kinase inhibition and HDAC inhibition,
    important targets in the treatment of oncology.

    Company: Evotec AG
    Ticker Symbol & Exchange: FSE: EVT
    Investor Relations Contact: Anne Hennecke, 49-40-56081-286
    Web: anne.hennecke@evotec.com
    Date of Presentation: 14 May 2007, 05.20 pm
    Evotec is a leader in the discovery and development of novel small
    molecule drugs.

    In proprietary projects, Evotec specialises in finding new treatments
    for diseases of the central nervous system. Evotec has three
    programmes in clinical development: EVT 201 (GABAA modulator) for the
    treatment of insomnia, EVT 101 (NMDA NR2B subtype antagonist) for the
    treatment of Alzheimer's disease/pain and EVT 302 (MAO-B inhibitor)
    in development for smoking cessation.

    In contract research, Evotec has established itself as the partner of
    choice for pharmaceutical and biotechnology companies worldwide. The
    Company provides innovative and often integrated solutions from drug
    target to clinic through an unmatched range of capabilities,
    including early stage assay development/screening through to
    medicinal chemistry and drug manufacturing.

    Company: GammaCan International Inc.
    Ticker Symbol & Exchange: OTC BB: GCAN
    Investor Relations Contact: Yaron Cherny, 972 3 738 2616 / 972 54 399
    1313
    Web: www.GammaCan.com
    Date of Presentation: May 14th
    GammaCan (OTCBB: GCAN) develops immunotherapies to treat cancer.
    VitiGam(TM) is GammaCan's lead program in development for the
    treatment of stage III and stage IV melanoma. Based on having
    demonstrated potent anti-melanoma activity in animal models,
    VitiGam(TM) is expected to enter Phase I/II trials under an U.S. IND
    in 2008. VitGam(TM) is an IgG-based product manufactured from plasma
    of donors with vitiligo, a benign skin condition. GammaCan owns U.S.
    patents covering uses of IgG to treat cancer and vitiligo-derived IgG
    (VitiGam(TM)) to treat melanoma. GammaCan has additional pending
    patent applications covering IgG-based therapies. GammaCan is located
    in Israel and the U.S.

    Company: Genetic Immunity
    Investor Relations Contact: Dr. Julianna Lisziewicz, 36-30-550-5596
    Web: www.geneticimmunity.com
    Date of Presentation: May 14, from 12:15 to 12:35 PM Zephyr
    Salon
    Genetic Immunity, a US-Hungarian biopharmaceutical enterprise, is a
    leader in the development of proprietary DNA nanoparticle-based
    topical cellular vaccines. The lead product, DermaVir Patch for the
    treatment of HIV/AIDS, has been demonstrated safe and effective in
    NIH sponsored primate studies. A Phase I clinical trial demonstrated
    safety and long-lived cellular immunogenicity in HIV-infected
    individuals. NIH and Karolinska Institute sponsored Phase II trials
    are underway in the US and EU. Product pipeline based on the
    Company's patented platform technology is under development through
    the Vaccine Therapy Cluster (www.vaccinetherapy.eu).

    Company: GENFIT
    Ticker Symbol & Exchange: ALGFT
    Investor Relations Contact: Guillaume LOHR, 33 (0)6 07 34 14 77,
    Guillaume.lohr@genfit.com
    Date of Presentation: 5/14/2007
    Genfit is an innovative biopharmaceutical company, enabling and
    developing 'first in class' or 'best to market' medicines for the
    prevention and treatment of cardiometabolic disease, the leading
    cause of mortality in the world.

    Located in Lille, (France) and Cambridge (MA, USA), Genfit scientific
    foundations are based on the renown expertise of Prof. Jean-Charles
    Fruchart and Prof Bart Staels, and has been managed from inception by
    Mr Jean-Francois Mouney, combining many years of experience in both
    business and science. Genfit nurtures innovative drug research in an
    advanced scientific environment, with clinical output as the key
    permanent objective.

    Genfit's mission is to discover and develop innovative new chemical
    entities targeting metabolic diseases, inflammatory disorders, and
    more generally cardiometabolic risk factors (dyslipidemia,
    atherosclerosis, diabetes, obesity, hypertension, neurodegenerative
    diseases...): Our aim is to improve the care of patients by
    researching and developing today, better and safer treatments for the
    future either based on new therapeutic targets (with a strong focus
    on nuclear receptors), or on a "multimodal drug discovery approach",
    targeting several indications simultaneously.

    With a unique partnering track-record, Genfit recognizes that
    pharmaceutical R&D needs multiple types of expertise and resources,
    and our company culture values alliances with leading international
    pharmaceutical groups, at different stages on the drug discovery and
    development value chain.

    Company: Glycadia Pharmaceuticals
    Investor Relations Contact: Perry M. Cohen, (215) 557-8021
    Web: Glycadia.com
    Date of Presentation: 5/14/2007
    Glycadia is developing drugs to treat kidney, eye and cardiovascular
    complications of diabetes. These innovative and proprietary therapies
    target upstream diabetes-specific abnormalities contributory to these
    disorders that result from diabetes.

    The prevalence of diabetes and its complications has reached epidemic
    proportions. There are no drugs available that directly target
    diabetes-specific abnormalities underlying the microvascular and
    macrovascular diseases associated with diabetes.

    Glycadia's lead candidate, GLY-230, an orally active small molecule,
    is in clinical trials for diabetic nephropathy. Submission of Phase
    2b protocols is expected in the second half of 2007.

    Company: Hollis-Eden Pharmaceuticals, Inc.
    Ticker Symbol & Exchange: NASDAQ: HEPH
    Investor Relations Contact: Scott A. Rieger, 858-587-9333
    Web: www.holliseden.com
    Date of Presentation: 15-May-07
    Hollis-Eden Pharmaceuticals is the world leader in the development of
    a proprietary class of small molecule compounds that are metabolites
    or synthetic analogs of endogenous adrenal steroid hormones. The
    Company's clinical drug development candidates include HE3286, a
    next-generation compound being prepared for clinical trials in
    treating type 2 diabetes and potentially rheumatoid arthritis, and
    HE3235, selected for clinical development in cancer. In addition,
    Hollis-Eden has an active research program that is generating
    additional new clinical leads that are being further evaluated in
    preclinical models of a number of different diseases.

    Company: Hunter-Fleming Ltd
    Investor Relations Contact: Dr Michael Capaldi, 44 117 900 8265
    Web: www.hunter-fleming.com
    Date of Presentation: Tuesday 15th May
    Dr Mike Capaldi, CEO of Hunter-Fleming Ltd. will be presenting the
    latest developments at the UK based biopharmaceutical company to the
    Rodman & Renshaw Global Healthcare Conference on 15th May 2007.

    Hunter-Fleming specializes in the development of innovative medicines
    to treat inflammatory degenerative diseases. The Company's lead
    product is currently in phase II clinical development for Alzheimer's
    disease. Two further products are in phase I clinical development
    with a further compound series in lead optimization. A fifth product
    for asthma and other autoimmune diseases has been out-licensed to
    Trident Pharmaceuticals and will enter pre-clinical toxicology during
    2007.

    Company: ImClone Systems Incorporated
    Ticker Symbol & Exchange: IMCL
    Investor Relations Contact: Rebecca Gregory, 646-638-5058
    Web: www.imclone.com
    Date of Presentation: Monday, May 14, 2007
    ImClone Systems Incorporated is committed to advancing oncology care
    by developing a portfolio of targeted biologic treatments designed to
    address the medical needs of patients with a variety of cancers. The
    Company's research and development programs include growth factor
    blockers and angiogenesis inhibitors. ImClone Systems' strategy is to
    continue to grow into a fully integrated biopharmaceutical company,
    taking its development programs from the research stage to clinical
    impact, and, ultimately, commercialization. ImClone Systems'
    headquarters and research operations are located in New York City,
    with clinical, regulatory, medical affairs, commercial,
    manufacturing, and additional administrative functions in Branchburg,
    New Jersey.

    Company: Locus Pharmaceuticals, Inc.
    Investor Relations Contact: Robert Dickey IV, 215-358-2006
    Web: www.locuspharma.com
    Date of Presentation: 15-May-07
    Locus is a world leader in computational drug design. The Company's
    core technology is a fragment-based, computational approach, which
    Locus has combined with highly integrated medicinal chemistry,
    crystallography and biology capabilities to create a unique drug
    design and development platform. Locus is using its capabilities to
    develop its own compounds and has also entered into drug
    design/development collaborations with pharmaceutical partners. All
    of the Company's internal development programs emanate from its
    computational technology and are focused on oral drug therapies,
    principally in cancer and inflammation.

    Company: LORUS THERAPEUTICS INC.
    Ticker Symbol & Exchange: AMEX: LRP & TSX: LOR
    Investor Relations Contact: Dr. Saeid Bababei, MBA., PhD., 416 798
    1200 x 490
    Web: www.lorusthera.com
    Date of Presentation: 14-May-07
    Lorus Therapeutics Inc. is a public Canadian biopharmaceutical Company
    engaged in the discovery and development of innovative, effective and
    safe products for the treatment of patients with cancer. Lorus' goal
    is to capitalize on its research, preclinical, clinical and
    regulatory expertise by developing new drug candidates that can be
    used, either alone, or in combination, to successfully manage cancer.

    Company: Maxygen, Inc.
    Ticker Symbol & Exchange: Nasdaq: MAXY
    Investor Relations Contact: Michele Boudreau, 650-279-2088
    Web: www.maxygen.com
    Date of Presentation: May 15, 11:10 am
    Maxygen is a biopharmaceutical company focused on developing improved
    versions of protein drugs. We look for opportunities where our
    proprietary protein modification technologies can address significant
    therapeutic needs. Products developed by Maxygen now in clinical
    trials include a novel interferon-alpha for the treatment of
    hepatitis C virus (HCV) infection and a novel G-CSF for the treatment
    of neutropenia. Maxygen's approach may allow us to leverage the
    established development and regulatory paths of approved drugs. We
    believe this advantage translates to a greater chance of successfully
    bringing important new drugs to market.

    Company: Medgenics, Inc.
    Investor Relations Contact: Andrew Pearlman, Phyllis Bellin; 972-4-
    9588555, 972-54-2274827
    Web: www.medgenics.com
    Date of Presentation: May 15, 2007 , 3:15 pm, Atlantique Salon
    Medgenics Inc. is a biopharmaceutical company developing a platform
    technology to provide sustained-action protein therapy for the
    treatment of a range of diseases, starting with anemia and hepatitis
    C. Medgenics has already shown proof-of-principle of the Biopump to
    deliver erythropoietin (EPO) in a clinical trial to anemic patients.
    The Company is developing two products based on its sustained-action
    Biopump technology: EPODURE producing EPO to treat anemia, and
    INFRADURE producing interferon-alpha to treat hepatitis C. For more
    information visit www.medgenics.com.

    Company: MediGene AG
    Ticker Symbol & Exchange: MDG
    Investor Relations Contact: Dr. Michael Nettersheim,
    investor@medigene.com, 49 - 89 - 85 65 -
    2946
    Web: www.medigene.com
    Date of Presentation: May 15th 2007, 12:55 PM
    MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG)
    biotechnology company located in Martinsried/Munich, Germany, with
    subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first
    German biotech company with a drug on the market. A second drug has
    been approved by the FDA. In addition, several drug candidates for
    the treatment of cancer and autoimmune diseases are currently in
    clinical development. MediGene also possesses innovative platform
    technologies.

    Company: Medivation, Inc.
    Ticker Symbol & Exchange: Nasdaq: MDVN
    Investor Relations Contact :Patrick Machado, 415-543-3470 (IR) or Jani
    Bergan, 415-946-106 (PR)
    Web: www.medivation.com
    Date of Presentation: 14-May-07
    Medivation, Inc. is a biopharmaceutical company with small molecule
    drugs in development to treat three large, unmet medical needs -
    Alzheimer's disease, Huntington's disease and hormone-refractory
    prostate cancer. The Company intends to build and maintain a
    portfolio of four to six development programs at all times.
    Dimebon(TM), the Company's lead product candidate, is currently being
    studied in clinical trials in patients with Alzheimer's disease and
    Huntington's disease. Six-month results from a Phase 2 trial in
    Alzheimer's disease demonstrated that Dimebon met all five efficacy
    endpoints with strong statistical significance compared with placebo.

    Company: Morria Biopharmaceuticals Plc
    Investor Relations Contact: Yuval Cohen, 44 (0)207 152 6341
    Web: www.morria.com
    Date of Presentation: May 14th
    Morria Biopharmaceuticals Plc. is a UK based drug development company
    focused on novel anti-inflammatory drugs. Morria's lead products are
    first-in-class, non-steroidal, synthetic anti-inflammatory drugs
    termed Multi-Functional Anti-Inflammatory Drugs (MFAID). The company
    has pre-clinical and clinical programs in dermatology, (contact
    dermatitis), respiratory (allergic rhinitis and cystic fibrosis) and
    gastro-intestinal inflammatory diseases (Inflammatory Bowel Disease).
    Morria is also engaged in Discovery Partnerships with Big Pharma in
    the fields of eyecare, ophthalmology and cardiovascular health.

    Company: Neose Technologies, Inc.
    Ticker Symbol & Exchange: Nasdaq GM: NTEC
    Investor Relations Contact: Barbara Krauter, 215-315-9004
    Web: www.neose.com
    Date of Presentation: 15-May-07
    Neose Technologies, Inc. is a clinical-stage biopharmaceutical company
    focused on the development of next-generation therapeutic proteins
    that are competitive with best-in-class protein drugs currently on
    the market, on its own and through strategic partnerships. The lead
    candidates in its pipeline, NE-180 for use in the treatment of
    chemotherapy-induced anemia and anemia associated with chronic renal
    failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia,
    target markets with aggregate sales in excess of USD 15 billion. For
    more information, please visit www.neose.com.

    Company: NicOx
    Ticker Symbol & Exchange: Euronext: NICOX
    Investor Relations Contact :Karl Hanks; 33 (0)4 97 24 53 43;
    hanks@nicox.com and Irene Lalande; 33
    (0)4 97 24 53 11; lalande@nicox.com
    Web: www.nicox.com
    Date of Presentation: 15-May-07
    NicOx is a product-driven biopharmaceutical company dedicated to the
    development of nitric oxide-donating drugs to meet unmet medical
    needs. NicOx is targeting the therapeutic areas of inflammatory and
    cardio-metabolic diseases. Resources are focused on two lead
    compounds, naproxcinod, in phase 3 development for the treatment of
    osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes. NicOx
    has strategic partnerships with some of the world's leading
    pharmaceutical companies, including Pfizer Inc. and Merck and Co.,
    Inc.

    NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a
    public company listed on the Eurolist of Euronext Paris (segment:
    Next Economy).

    Company: NovaDel Pharma
    Ticker Symbol & Exchange: AMEX: NVD
    Investor Relations Contact: Susan H. Griffin, 908-782-3431 ext. 2423,
    sgriffin@novadel.com
    Web: www.novadel.com
    Date of Presentation: Tuesday, May 15, 2007 @ 11:10a.m.
    NovaDel Pharma Inc. is a specialty pharmaceutical company developing
    oral spray formulations of a broad range of marketed treatments. The
    Company's proprietary oral spray technology offers the patient the
    potential for (i) more rapid absorption of drugs to the bloodstream
    compared to conventional oral dosage forms; (ii) limited first pass
    liver metabolism; (iii) avoiding the need to swallow; (iv) allowing
    medication to be taken without water; (v) improved drug safety
    profile by reducing the required dosage; and (vi) improved patient
    convenience and compliance. NovaDel's most advanced candidates target
    nausea, insomnia, migraine headaches and disorders of the central
    nervous system (CNS).

    Company: Novelos Therapeutics, Inc.
    Ticker Symbol & Exchange: OTCBB: NVLT
    Investor Relations Contact: Stephen Lichaw, 201-240-3200
    Web: www.novelos.com
    Date of Presentation: May 14, 2007, 9:45am
    Novelos Therapeutics, Inc. is a biopharmaceutical company
    commercializing oxidized glutathione-based compounds for the
    treatment of cancer and hepatitis. NOV-002, the lead compound
    currently in Phase 3 development for lung cancer under a SPA and Fast
    Track, acts together with chemotherapy as a chemoprotectant and an
    immunomodulator. NOV-002 is also in Phase 2 development for
    chemotherapy-resistant ovarian cancer and early-stage breast cancer,
    and is in addition being developed for acute radiation injury. NOV-
    205 acts as a hepatoprotective agent with immunomodulating and anti-
    inflammatory properties. NOV-205 is in Phase 1b development for
    chronic hepatitis C non-responders. Both compounds have completed
    clinical trials in humans and have been approved for use in the
    Russian Federation where they were originally developed.

    Company: OMRIX Biopharmaceuticals, Inc.
    Ticker Symbol & Exchange: NASDAQ: OMRI
    Investor Relations Contact: Francesca DeMartino, 212-887-6510
    Web: www.omrix.com
    Date of Presentation: May 14, 2007; 9:45 AM (Local Time)
    OMRIX is a profitable, fully-integrated biopharmaceutical company
    developing and marketing protein-based biosurgery and passive
    immunotherapy products. We utilize our proprietary protein
    purification technology and manufacturing know-how to develop
    products within our diversified and synergistic business platforms
    and establish a presence in growing and under-penetrated markets. Our
    biosurgery product line includes products and product candidates,
    such as liquid fibrin sealants and thrombin products, used for the
    control of bleeding, or hemostasis, and other surgical applications.
    Our passive immunotherapy product line includes antibody-rich
    products and product candidates for the treatment of immune
    deficiencies, infectious diseases and potential biodefense
    applications.

    Company: Orexo AB
    Ticker Symbol & Exchange: ORX (SSE)
    Investor Relations Contact: Mr Claes Wenthzel, Executive Vice
    President & CEO, 46 18 780 88 00
    Web: www.orexo.com
    Date of Presentation: 15-May-07
    Orexo AB is a pharmaceutical company developing new pharmaceutical
    drugs within areas currently subject to considerable unmet medical
    needs. Orexo applies its broad expertise in medicine and
    pharmaceuticals to the further development of existing pharmaceutical
    substances. By combining well-documented compounds with its own
    patented drug delivery methods and its unique expertise in "dry
    formulations" (for example, tablets), Orexo is able to develop new
    patented pharmaceuticals.

    Orexo has grown into an organization with 67 full-time employees, most
    of whom are active in research and development, clinical development
    and pharmaceutical registration. At present, the company has two
    products on the market, three products in late clinical development
    phase - one of which has been out-licensed in the US, Europe and
    Japan and submitted for registration in Europe - and two projects in
    pharmaceutical formulation phase. Orexo has adopted an active
    intellectual property rights strategy and has, since its inception,
    built up an extensive patent portfolio to protect its products and
    technologies.

    Company: PAION AG
    Ticker Symbol & Exchange: PA8, Frankfurt Stock Exchange
    Investor Relations Contact: Dr. Peer Nils Schroeder, 49-241-4453-152
    Web: www.paion.de
    Date of Presentation: 14-May-07
    PAION, a biopharmaceutical company based in Aachen, Germany, aims to
    become a leader in developing and commercialising innovative drugs
    for the treatment of stroke and other thrombotic diseases for which
    there is a substantial unmet medical need. PAION intends to build an
    integrated drug portfolio by exploiting its expertise in identifying
    compounds, licensing or otherwise acquiring them and advancing them
    through the clinical development and regulatory approval process.
    Results for the Phase III study of PAION's lead product Desmoteplase
    will be presented 1 June 2007. In 2006, PAION employed on average 77
    people.

    Company: Pipex Pharmaceuticals, Inc.
    Ticker Symbol & Exchange: PPXP (OTCBB)
    Investor Relations Contact: Thomas Redington, 203-222-7399
    Web: www.pipexpharma.com
    Date of Presentation: 5/15/2007
    Pipex Pharmaceuticals, Inc. is a specialty pharmaceutical company that
    is developing proprietary, late-stage drug candidates for the
    treatment of neurologic and fibrotic diseases. Pipex's lead product,
    COPREXA(TM) (oral tetrathiomolybdate) has completed pivotal clinical
    trials for an orphan genetic disease, known as neurologic Wilson's
    disease and has also completed phase II clinical trials for
    Idiopathic Pulmonary Fibrosis (IPF), a deadly lung disease.

    Pipex is also developing TRIMESTA(TM) (oral estriol) for the treatment
    of multiple sclerosis which has completed a phase II clinical trial.
    For further information, please visit, www.pipexpharma.com.

    Company: Prana Biotechnology Ltd.
    Ticker Symbol & Exchange: PRAN: NASDAQ / PBT: ASX (Australia)
    Investor Relations Contact: Kathy Price, 646-284-9430
    Web: www.pranabio.com
    Date of Presentation: 15-May-07
    Prana Biotechnology Ltd. is a biopharmaceutical company focused on the
    research and development of treatments for Alzheimer's disease and
    other age-related neurodegenerative disorders. Prana's discoveries,
    emerging out of Massachusetts General Hospital at Harvard University
    and the University of Melbourne in Australia, have lead to the
    development of MPAC's (Metal Protein Attenuating Compounds). MPAC's
    have shown great promise to treat a variety of neurodegenerative
    disorders. Clinical efficacy (phase 2) has earlier been demonstrated
    in a 'proof of principle' MPAC (PBT1) for Alzheimer's disease.
    Prana's lead proprietary molecule, PBT2, is currently in Phase IIa
    testing for Alzheimer's disease.

    Company: ProMetic Life Sciences Inc.
    Ticker Symbol & Exchange: PLI (TSX)
    Investor Relations Contact: Lippert/Heilshorn & Associates, Inc, Lisa
    Lindberg, (212) 838-3777
    Web: www.prometic.com
    Date of Presentation: May 15, 2007 - 3:15pm
    ProMetic Life Sciences Inc. is a biopharmaceutical company specialized
    in the research, development, manufacture and marketing of a variety
    of commercial applications derived from its proprietary Mimetic
    Ligand(TM) enabling technology. This technology is used in large-
    scale purification of biologics and the elimination of pathogens.
    ProMetic is also active in therapeutic drug development with the
    mission to bring to market effective, innovative, lower cost, less
    toxic products for the treatment of inflammation and cancer. Its drug
    discovery platform is focused on replacing complex, expensive
    proteins with synthetic "drug-like" protein mimetics. Headquartered
    in Montreal, Canada, ProMetic has R&D and manufacturing facilities in
    the UK and business development activities in the US, Europe, Asia
    and MENA countries (Middle East and North Africa).

    Company: Protherics PLC
    Ticker Symbol & Exchange: LSE: PTI, NASDAQ: PTIL
    Investor Relations Contact: Nick Staples, 44 (0)20 7246 9950 or 44
    (0)7919 480 510
    Web: www.protherics.com
    Date of Presentation: 10.50am Tuesday 15 May
    Protherics PLC is a leading biopharmaceutical company focused on the
    development, manufacture and marketing of specialised products for
    critical care and cancer.

    Protherics has developed and manufactures two biologics for critical
    care which are FDA approved and currently sold in the US: CroFab(TM),
    a pit viper antivenom and DigiFab(TM), a digoxin antidote. The
    Company's strategy is to use the revenues generated from its marketed
    and out-licensed products to help fund the advancement of its broad,
    late stage pipeline.

    Protherics has two major development opportunities in its critical
    care portfolio. CytoFab(TM) is being developed by AstraZeneca for the
    treatment of severe sepsis and Digoxin Immune Fabs for the treatment
    of pre-eclampsia. Protherics also has a pipeline of four novel cancer
    products in clinical development.

    With headquarters in London, the Company has approximately 260
    employees in the UK, US and Australia. For further information please
    visit www.protherics.com

    Company: Starpharma Holdings Limited
    Ticker Symbol & Exchange: ASX:SPL, OTCQX: SPHRY
    Investor Relations Contact: Jennifer K. Zimmons, Ph.D.; 212-838-1444
    or Dr Jackie Fairley, CEO; 61 3 8532
    2704, 61 407 716 887 (Cell)
    Web: www.starpharma.com
    Date of Presentation: Tuesday May 15, 2007 - 9:45am
    Starpharma is pioneering the development of dendrimer nanotechnology
    products for pharmaceutical, life science, and other applications.

    Lead product, VivaGel(TM), is a vaginal microbicide designed to
    prevent the transmission of Sexually Transmitted Infections
    (specifically HIV and genital herpes). Currently in human clinical
    trials, VivaGel(TM) has received US FDA Fast Track status and more
    than USD 20M in non-dilutive support from the NIH. VivaGel(TM)
    addresses multi-billion dollar markets aimed at preventing sexually
    transmitted infections. The product has also shown activity as a
    contraceptive and the active ingredient has potential application as
    a condom coating agent.

    Through the 2006 acquisition of US-based Dendritic Nanotechnologies,
    Starpharma has expanded its product pipeline to include drug
    delivery, siRNA transfection and industrial chemical applications.
    Through DNT the company has royalty-bearing relationships with Dade
    Behring, Qiagen, Sigma, Aldrich and EMD Biosciences.

    With an active American Depositary Receipts (ADR) program
    (OTCQX:SPHRY) in place, Dow Chemical (NASDQ:DOW) as lead shareholder,
    and US offices, Starpharma is actively embracing the US market.
    Currently more than 20% of Starpharma's shares are held by US
    investors, with DOW holding 8.6%.

    Company: Tercica, Inc.
    Ticker Symbol & Exchange: Nasdaq: TRCA
    Investor Relations Contact: Fredrik Wiklund, 650-624-4992
    Web: www.tercica.com
    Date of Presentation: 5/14/07 at 9:00 a.m. local time
    Tercica is a biopharmaceutical company committed to improving
    endocrine health by partnering with the endocrine community to
    develop and commercialize new therapeutics for short stature and
    other metabolic disorders. For further information on Tercica, please
    visit www.tercica.com.

    Company: UTEK Corporation
    Ticker Symbol & Exchange: AMEX: UTK and LSE-AIM: UTK
    Investor Relations Contact: Steve Liebmann or Simon Bloomfield, 44 (0)
    20-7367-8883
    Web: www.utekcorp.com
    Date of Presentation: Monday, May 14, 2007
    UTEK(R) is a specialty finance company focused on technology transfer.
    UTEK's services enable companies to rapidly acquire innovative
    technologies from universities and research laboratories worldwide in
    exchange for their equity securities. This unique process is called
    U2B(R). In addition, UTEK offers companies the tools to search, and
    analyze intellectual properties. UTEK is a business development
    company with operations in the United States, United Kingdom and
    Israel.

    Company: ViroPharma Incorporated
    Ticker Symbol & Exchange: Nasdaq: VPHM
    Investor Relations Contact: Will Roberts, 610-321-6288
    Web: www.viropharma.com
    Date of Presentation: 5/14/2007
    ViroPharma Incorporated is committed to the development and
    commercialization of products that address serious diseases treated
    by physician specialists and in hospital settings. ViroPharma
    commercializes Vancocin(R) approved for oral administration for
    treatment of antibiotic-associated pseudomembranous colitis caused by
    Clostridium difficile and enterocolitis caused by Staphylococcus
    aureus, including methicillin-resistant strains (for prescribing
    information, please download the package insert at
    http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma
    currently focuses its drug development activities in viral diseases
    including cytomegalovirus (CMV) and hepatitis C virus (HCV).

    Company: XYTIS
    Investor Relations Contact: Vincent F. Simmon, Chairman, President &
    CEO, 949 226 1118
    Web: www.xytis.com
    Date of Presentation: May 14th 2007 at 9:45AM
    Xytis is a CNS small molecule private company formed in 2005 by the
    merger of Xytis Pharmaceuticals Ltd. and Remergent Inc. Current
    investors are Atlas Venture, Sanderling, CDC Entreprises, and
    Ventech. Xytis pipeline includes two compounds in the clinic. XY2405,
    an inhibitor of Bradykinin B2 receptor, is in PhII trial for
    Traumatic Brain Injury. XY2401, currently in PhIb, is an anti-
    psychotic agent that was shown to improve cognitive performance and
    revealed anxiolytic and anti-depressive activity in animal models. In
    addition, Xytis has a rich portfolio of preclinical compounds that
    are highly selective positive allosteric modulators of nicotinic
    Acetylcholine and GABAA receptors being readied for IND filing.

    Company: ZIOPHARM Oncology, Inc.
    Ticker Symbol & Exchange: ZIOP: NASDAQ
    Investor Relations Contact: Suzanne McKenna, 646-214-0703
    Web: www.ziopharm.com
    Date of Presentation: 15-May-07
    ZIOPHARM Oncology is a biopharmaceutical company engaged in the
    development and commercialization of a diverse, risk-sensitive
    portfolio of in-licensed cancer drugs to address unmet medical needs.
    The Company applies new insights from molecular and cancer biology to
    understand the efficacy and safety limitations of approved and
    developmental cancer therapies and identifies proprietary and related
    molecules for better patient treatment.
    *T

    Note to Editors: Business Wire's PressPass allows you to create
    free, custom Web, RSS, and email-based news feeds from more than 160
    industry options, dozens of subject categories and thousands of
    geographic preferences as well as by specific company filters. In
    addition, PressPass subscribers have access to exclusive content,
    experts, company profiles, email alerts, survey services and other
    media services.

    Note to Event Organizers: Add your trade show, conference, or
    event to http://www.tradeshownews.com, Business Wire's online event
    calendar. For information, email tradeshow@businesswire.com.